What the April 2026 Announcement Changes The FDA's April 15 announcement signals that injectable GHK-Cu will be removed from the Category 2 list, with formal implementation expected in July 2026 when the FDA's peptide advisory panel is scheduled to reconvene and finalize updated guidance
TB-500 CALCULATOR Calculate TB-500 doses for loading and maintenance phases TB-500 (Thymosin Beta-4) uses different dosing than most peptides
Side Effects Possible side effects include mild irritation at the injection site, allergic reactions, or, rarely, anaphylaxis
Anti-inflammatory peptides typically target more specific pathways NF-kB signaling, mitochondrial ROS, or sirtuin activation which may offer more selective anti-inflammatory effects
Key Takeaways 5-Amino-1MQ is a small molecule that inhibits the NNMT enzyme, a regulator studied in cellular energy and methylation pathways
What is BPC-157